All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Durvalumab Plus Concurrent Chemoradiotherapy Fails to Show PFS or OS Benefit in NSCLC

November 28th 2025

Durvalumab administered with chemoradiotherapy rather than afterwards generated no significant improvement in PFS, OS, or ORR for patients with NSCLC.

Vorasidenib Demonstrates Favorable Safety Profile and Disease Stability in High-Grade IDH-Mutant Gliomas

November 27th 2025

Retrospective data showed vorasidenib displayed strong disease stability in addition to being well tolerated in grade 3 or 4 IDH-mutant glioma.,

Dana-Farber Cancer Institute is Awarded $20 Million Grant From the Elaine and Eduardo Saverin Foundation

November 27th 2025

Dana-Farber Cancer Institute was awarded a $20 million grant by The Elaine and Eduardo Saverin Foundation for advancements in metastatic breast cancer.

Modest Efficacy Outcomes Necessitate Broader Clinical Considerations for Later-Line Treatment Selection in Refractory CRC

November 26th 2025

Tiago Biachi, MD, PhD, reviews how data from the CORRECT, SUNLIGHT, and FRESCO trials inform later-line treatment selection in refractory mCRC.

DESTINY-Endometrial01 Will Examine T-DXd Plus Rilvegostomig or Pembrolizumab in HER2+ pMMR Endometrial Cancer

November 26th 2025

Vicky Makker, MD, discusses the DESTINY-Endometrial01 trial of T-DXd plus rilvegostomig or pembrolizumab in HER2+ pMMR endometrial cancer.

Mayo Clinic Researchers Identify Why Some Lung Tumors Respond Well to Immunotherapy

November 26th 2025

Mayo Clinic researchers have found previously unknown genetic and cellular processes that occur in lung cancers that respond well to immunotherapy.

Ziftomenib Added to NCCN Clinical Practice Guidelines for NPM1-Mutant R/R AML

November 26th 2025

The NCCN guidelines for AML have been updated to include ziftomenib as a category 2A recommendation for NPM1-mutant, relapsed/refractory AML management.

FDA Grants Priority Review to Sonrotoclax for R/R Mantle Cell Lymphoma

November 26th 2025

Sonrotoclax is under priority review by the FDA for the treatment of adult patients with relapsed or refractory, BTK inhibitor–pretreated MCL.

Evolving Approaches With BTK Inhibition and Targeted Therapy Seek to Improve Outcomes in High-Risk MCL

November 26th 2025

Christine Ryan, MD, discusses the limitations of current MCL treatment strategies, advances in treatment, and the evolving role of BTK inhibition.

T-DM1 Displays a Lower Cardiotoxicity Risk vs Other HER2-Targeted Regimens in HER2+ Breast Cancer

November 26th 2025

T-DM1 showed the lowest LVEF decline vs other HER2-targeted regimens, underscoring key differences in cardiac safety.

HER2-Mutated NSCLC: A Therapeutic Breakthrough

November 26th 2025

Experts discuss insights and considerations for identifying and managing HER2-mutated non–small cell lung cancer.

Intraventricular B7-H3–Targeted CAR T-Cell Therapy Displays Safety in Recurrent Glioblastoma

November 25th 2025

B7-H3–directed CAR T cell therapy was well-tolerated and demonstrated an acceptable safety profile in recurrent glioblastoma.

FDA Approves Perioperative Durvalumab for Resectable Gastric/GEJ Adenocarcinoma

November 25th 2025

The FDA approved durvalumab plus FLOT for the perioperative treatment of resectable gastric and gastroesophageal junction cancers.

Cevostamab-Based Combos Could Represent Next Bispecific Antibody Approach in R/R Myeloma

November 25th 2025

Joshua Richter, MD, discusses the evaluation of the FcRH5 x CD3 bispecific antibody in multiple myeloma.

European Commission Approves Liso-Cel for R/R Mantle Cell Lymphoma

November 25th 2025

Liso-cel was approved in the EU for relapsed/refractory MCL after at least 2 lines of therapy, including a BTK inhibitor.

Subcutaneous Toripalimab Plus Chemo Meets PK End Points in Recurrent/Metastatic Nonsquamous NSCLC

November 25th 2025

Subcutaneous toripalimab generated non-inferior efficacy and safety outcomes vs the IV formulation in recurrent/metastatic non squamous NSCLC.

Roswell Park Expands EDDY Program with Region’s First Mobile Screening Center for Breast and Prostate Cancer

November 25th 2025

Roswell Park Comprehensive Cancer Center unveiled a comprehensive mobile cancer screening initiative for breast and prostate cancer.

FDA Grants Orphan Drug Designation to OBI-902 in Cholangiocarcinoma

November 25th 2025

OBI-902 received orphan drug designation from the FDA for the treatment of patients with cholangiocarcinoma.

ctDNA Insights Stand at the Forefront of Data-Driven, Individualized MIBC Management

November 25th 2025

In a recent Peer Exchange, bladder cancer experts reviewed the current treatment paradigm for muscle-invasive bladder cancer (MIBC) and discussed updates from ESMO 2025.

Vorasidenib Reduces Tumor Growth Rate in IDH1/2-Mutant Grade 2 Glioma

November 24th 2025

INDIGO TGR analyses showed vorasidenib markedly slowed tumor growth and improved PFS and TTNI vs placebo in IDH1/2-mutant grade 2 glioma.